Desacidificación por destilación mediante arrastre con nitrógeno. Posible aplicación a la refinación de grasas comestibles

The possibility of substituting direct steam by nitrogen as stripper in the deodorizing or neutralizing distillation of oils and fats has been the subject of research in recent years. Although this is a practical possibility, it implies a greater cost due to the higher price of nitrogen, and the need to adapt the technology in order to maintain the deodorizer head pressure (as nitrogen does not condensate). These disadvantages would be compensated by a better quality of the oils and condensates, and a decrease in pollution. The tests carried out indicate that the efficiency calculated in each of the operations is within the theoretical values, and that using from 1 to 1.5 times the theoretical amount of nitrogen, the refined oils are graded physically as good and very good by an expert. The condensates obtained have been of good quality.En los últimos años se está investigando la posibilidad de sustituir por nitrógeno el vapor de agua directo utilizado en la desodorización o la destilación neutralizante de aceites y grasas. Dicha posibilidad es factible, sin embargo implica un mayor costo debido al mayor precio del nitrógeno, y una necesidad de adecuar la tecnología para mantener la presión en cabeza del desodorizador (al no condensar el nitrógeno). Estos inconvenientes deben ser solventados por una mejor calidad de los aceites, de los condensados y por una disminución de la contaminación. Los ensayos realizados indican que la "eficacia" calculada en cada una de las operaciones realizadas está dentro de los valores teóricos; y que los aceites refinados físicamente, mediante el paso de 1 a 1,5 veces la cantidad teórica de nitrógeno, tienen calificaciones de bueno y muy bueno dadas por un experto. Los condensados obtenidos han sido de buena calidad

2-DE analysis of sera protein expression profiles in early stages of human neonatal development. A preliminary study.

Comunicaciones a congreso

Gene Therapy Corrects Mitochondrial Dysfunction in Hematopoietic Progenitor Cells and Fibroblasts from Coq9R239X Mice

This study has been submitted to the patent's offices at the "University of Granada" and "Fundación Progreso y Salud". Please note that the results of this manuscript have been submitted to patent protection (application number P201630630; title: “Uses of Coenzyme Q biosynthetic proteins”; date:05/16/2016).Recent clinical trials have shown that in vivo and ex vivo gene therapy strategies can be an option for the treatment of several neurological disorders. Both strategies require efficient and safe vectors to 1) deliver the therapeutic gene directly into the CNS or 2) to genetically modify stem cells that will be used as Trojan horses for the systemic delivery of the therapeutic protein. A group of target diseases for these therapeutic strategies are mitochondrial encephalopathies due to mutations in nuclear DNA genes. In this study, we have developed a lentiviral vector (CCoq9WP) able to overexpress Coq9 mRNA and COQ9 protein in mouse embryonic fibroblasts (MEFs) and hematopoietic progenitor cells (HPCs) from Coq9R239X mice, an animal model of mitochondrial encephalopathy due to primary Coenzyme Q (CoQ) deficiency. Ectopic over-expression of Coq9 in both cell types restored the CoQ biosynthetic pathway and mitochondrial function, improving the fitness of the transduced cells. These results show the potential of the CCoq9WP lentiviral vector as a tool for gene therapy to treat mitochondrial encephalopathies.This work was supported by grants from Ministerio de Economía y Competitividad (Spain) and the European Regional Development Fund (ERDF) from the European Union, to LCL through the research grants SAF2013-47761-R and SAF2015-65786-R; by Fondo de Investigaciones Sanitarias ISCIII (Spain) and the European Regional Development Fund (ERDF) from the European Union through the research grants PI12/01097 and ISCIII Red de Terapia Celular TerCel RD12/0019/0006 to FM; by the Consejería de Economía, Innovación, Ciencia y Empleo, Junta de Andalucía-FEDER/Fondo de Cohesion Europeo (FSE) de Andalucía through the research grants P10-CTS-6133 to LCL; P09-CTS-04532, PI-57069, PI-0001/2009 and PAIDI-Bio-326 to F.M.; PI-0160/2012 to KB and PI-0407/2012 to MC; by the NIH through the research P01HD080642 to LCL and by the foundation “todos somos raros, todos somos únicos” to LCL. LCL is supported by the ‘Ramón y Cajal’ National Programme, Ministerio de Economía y Competitividad, Spain (RYC-2011-07643)

Morbility, clinical data and proteomic analysis of IUGR and AGA newborns at different gestational ages

The data are related to the proteomic analysis of 43 newborns with intrauterine growth retardation (IUGR) and 45 newborns with appropriate weight for gestational age (AGA) carried out by separation via 2DE and analyzed by MS–TOF/TOF. All newborns were separated into three gestational age groups, "Very Preterm" 29–32 weeks, "Moderate Preterm" 33–36 weeks, and, "Term" ≥37weeks. From each newborn, blood was drawn three times from birth to 1 month life. High-abundant serum proteins were depleted, and the minority ones were separated by 2DE and analyzed for significant expression differences. The data reflect analytic and clinic variables analyzed globally and categorized by gestational age in relation to IUGR and the optimization of conditions for 2-DE separation. The data from this study are related to the research article entitled "Alterations of Protein Expression in Serum of Infants with Intrauterine Growth Restriction and Different Gestational Ages" (M.D. Ruis-González, M.D. Cañete, J.L. Gómez-Chaparro, N. Abril, R. Cañete, J. López-Barea, 2015) [1]. The present dataset of serum IUGR newborn proteome can be used as a reference for any study involving intrauterine growth restriction during the first month of life